These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8902409)

  • 1. Accurate characterization of ofloxacin susceptibility with Enterobacteriaceae using a modified GNS F6 card and the bioMerieux Vitek System.
    Doern GV; Torres BB; Jankins M; Jones RN
    Diagn Microbiol Infect Dis; 1996 Jul; 25(3):133-5. PubMed ID: 8902409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter laboratory evaluation of the bioMérieux Vitek antimicrobial susceptibility testing system with 11 antimicrobial agents versus members of the family Enterobacteriaceae and Pseudomonas aeruginosa.
    Doern GV; Brueggemann AB; Perla R; Daly J; Halkias D; Jones RN; Saubolle MA
    J Clin Microbiol; 1997 Aug; 35(8):2115-9. PubMed ID: 9230393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of agar dilution, disk diffusion, MicroScan, and Vitek antimicrobial susceptibility testing methods to broth microdilution for detection of fluoroquinolone-resistant isolates of the family Enterobacteriaceae.
    Steward CD; Stocker SA; Swenson JM; O'Hara CM; Edwards JR; Gaynes RP; McGowan JE; Tenover FC
    J Clin Microbiol; 1999 Mar; 37(3):544-7. PubMed ID: 9986809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical evaluation of the Vitek GNS F6 card results compared to standardized, reference susceptibility test methods.
    Jones RN; Marshall SA; Zerva L
    Diagn Microbiol Infect Dis; 1997 May; 28(1):35-40. PubMed ID: 9218917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99).
    Jones RN; Pfaller MA;
    Diagn Microbiol Infect Dis; 2001 Apr; 39(4):237-43. PubMed ID: 11404067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-resistance and cross-susceptibility between fluoroquinolone agents.
    Barry AL; Fuchs PC
    Eur J Clin Microbiol Infect Dis; 1991 Dec; 10(12):1013-8. PubMed ID: 1666360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa.
    Kowalski RP; Pandya AN; Karenchak LM; Romanowski EG; Husted RC; Ritterband DC; Shah MK; Gordon YJ
    Ophthalmology; 2001 Oct; 108(10):1826-9. PubMed ID: 11581056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
    Gilbert DN; Kohlhepp SJ; Slama KA; Grunkemeier G; Lewis G; Dworkin RJ; Slaughter SE; Leggett JE
    Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. North American (United States and Canada) comparative susceptibility of two fluoroquinolones: ofloxacin and ciprofloxacin. A 53-medical-center sample of spectra of activity. North American Ofloxacin Study Group.
    Jones RN; Hoban DJ
    Diagn Microbiol Infect Dis; 1994 Jan; 18(1):49-56. PubMed ID: 8026157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in vitro activity of the new fluoroquinolone BMY-40062.
    Chin NX; Neu H
    Eur J Clin Microbiol Infect Dis; 1990 Aug; 9(8):620-4. PubMed ID: 2120060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The in vitro activity of ofloxacin, pefloxacin and ciprofloxacin against various gram negative bacteria isolated from urinary tract infections].
    Tunçkanat F; Yuluğ N
    Mikrobiyol Bul; 1988; 22(3):187-92. PubMed ID: 3252111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
    Hansen GT; Blondeau JM
    J Chemother; 2005 Oct; 17(5):484-92. PubMed ID: 16323436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ofloxacin, a new broad-spectrum fluoroquinolone. Results from a Multicenter, National Comparative Activity Surveillance Study. The Ofloxacin Surveillance Group.
    Jones RN; Reller LB; Rosati LA; Erwin ME; Sanchez ML
    Diagn Microbiol Infect Dis; 1992 Jul; 15(5):425-34. PubMed ID: 1643819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of the Vitek system for antimicrobial susceptibility testing Enterobacteriaceae bloodstream infection isolates: use of "direct" inoculation from Bactec 9240 blood culture bottles.
    Putnam LR; Howard WJ; Pfaller MA; Koontz FP; Jones RN
    Diagn Microbiol Infect Dis; 1997 Jun; 28(2):101-4. PubMed ID: 9239502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones.
    Alexandrakis G; Alfonso EC; Miller D
    Ophthalmology; 2000 Aug; 107(8):1497-502. PubMed ID: 10919897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
    Madhusudhan KT; Counts C; Lody C; Carter O; Dodson S; Ojha N
    Chemotherapy; 2003 Jul; 49(4):184-8. PubMed ID: 12886053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of 500 gram negative isolates to determine the number of major susceptibility interpretation discrepancies between the Vitek and MicroScan Walkaway for 9 antimicrobial agents.
    Rittenhouse SF; Miller LA; Utrup LJ; Poupard JA
    Diagn Microbiol Infect Dis; 1996 Sep; 26(1):1-6. PubMed ID: 8950521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct identification and susceptibility testing of enteric bacilli from positive blood cultures using VITEK (GNI+/GNS-GA).
    Hansen DS; Jensen AG; Nørskov-Lauritsen N; Skov R; Bruun B
    Clin Microbiol Infect; 2002 Jan; 8(1):38-44. PubMed ID: 11906499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.
    Kowalski RP; Dhaliwal DK; Karenchak LM; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ
    Am J Ophthalmol; 2003 Sep; 136(3):500-5. PubMed ID: 12967804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil.
    Oliveira AD; D'Azevedo PA; Francisco W
    Cornea; 2007 Feb; 26(2):194-8. PubMed ID: 17251812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.